NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $143.19 +0.39 (+0.27 %) (As of 11/20/2018 06:51 AM ET)Previous Close$142.80Today's Range$141.46 - $146.1952-Week Range$130.15 - $184.00Volume726,600 shsAverage Volume776,436 shsMarket Capitalization$8.61 billionP/E Ratio12.36Dividend YieldN/ABeta1.06 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland. Receive JAZZ News and Ratings via Email Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ Previous Symbol CUSIPG5087110 Webwww.jazzpharma.com Phone353-1634-7800 Debt Debt-to-Equity Ratio0.52 Current Ratio4.29 Quick Ratio4.16 Price-To-Earnings Trailing P/E Ratio12.36 Forward P/E Ratio12.34 P/E Growth0.79 Sales & Book Value Annual Sales$1.62 billion Price / Sales5.34 Cash Flow$13.0648 per share Price / Cash10.96 Book Value$45.26 per share Price / Book3.16 Profitability EPS (Most Recent Fiscal Year)$9.56 Net Income$487.84 million Net Margins28.09% Return on Equity24.92% Return on Assets13.36% Miscellaneous Employees1,210 Outstanding Shares60,320,000Market Cap$8.61 billion OptionableOptionable Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its earnings results on Tuesday, November, 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating analysts' consensus estimates of $3.32 by $0.26. The specialty pharmaceutical company earned $469.37 million during the quarter, compared to analysts' expectations of $482.64 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. The business's revenue was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.22 earnings per share. View Jazz Pharmaceuticals' Earnings History. When is Jazz Pharmaceuticals' next earnings date? Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Jazz Pharmaceuticals. What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.11. The company issued revenue guidance of $1.86-1.90 billion, compared to the consensus revenue estimate of $1.92 billion.Jazz Pharmaceuticals also updated its FY 2018 guidance to $12.75-13.25 EPS. What price target have analysts set for JAZZ? 17 brokers have issued twelve-month target prices for Jazz Pharmaceuticals' shares. Their forecasts range from $161.00 to $210.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $191.75 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals. What is the consensus analysts' recommendation for Jazz Pharmaceuticals? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals. What are Wall Street analysts saying about Jazz Pharmaceuticals stock? Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock: 1. According to Zacks Investment Research, "After lower-than-expected sales in 2017, Jazz’ sleep disorder drug, Xyrem witnessed improved volume trends in the first half. Management seems confident that Xyrem will continue to generate volume growth in 2018 and beyond. Jazz’s lead pipeline candidate JZP-110 complements its existing sleep disorder portfolio. Jazz is also actively evaluating business development deals to enhance its product line and pipeline. Shares of the company have outperformed the industry so far this year. However, Jazz has been facing supply constraints for its leukemia drug, Erwinaze, due to constrained manufacturing capacity. These supply challenges are expected to continue in 2018. Meanwhile, its newest drug Vyxeos performed below expectations and Jazz lowered its full-year outlook. Earnings estimates have gone down ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (11/13/2018) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and we are lowering our PT by $2 to $201 for JAZZ stock. We continue to believe management has positioned the company well for a solid financial performance in a post-Xyrem" world through innovation and diversification. We believe NT stock performance will be driven by potential FDA approval of solriamfetol and JZP-258 data in narcolepsy." (11/6/2018) 3. HC Wainwright analysts commented, "We highlighted after 1Q that management seemed to be taking a decidedly conservative approach to guidance this year, and this quarter we again see a healthy beat with little or no full-year raise. We still think guidance is a bit conservative (we’re near the high end on REV and EPS), but besides a small revenue drag from the sale of Prialt, unfortunately there was a key underperformer holding Jazz guidance back: Vyxeos. Jazz’s newest growth driver, from its most recent acquisition, only grew modestly QoQ, missed consensus for the second straight quarter, and Jazz lowered the product’s 2018 guidance 12% at the midpoint to $115-135M." (8/9/2018) 4. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018) Has Jazz Pharmaceuticals been receiving favorable news coverage? News headlines about JAZZ stock have trended very positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Jazz Pharmaceuticals earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Jazz Pharmaceuticals' key competitors? Some companies that are related to Jazz Pharmaceuticals include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Bausch Health Companies (BHC), Perrigo (PRGO), Genmab A/S (GNMSF) and Sarepta Therapeutics (SRPT). Who are Jazz Pharmaceuticals' key executives? Jazz Pharmaceuticals' management team includes the folowing people: Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)Mr. Matthew P. Young, Exec. VP & CFO (Age 49)Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 55) Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (9.52%), BlackRock Inc. (7.43%), Putnam Investments LLC (7.16%), JPMorgan Chase & Co. (3.17%), Bank of New York Mellon Corp (2.80%) and TIAA CREF Investment Management LLC (2.21%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals. Which institutional investors are selling Jazz Pharmaceuticals stock? JAZZ stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Putnam Investments LLC, Partner Fund Management L.P., Epoch Investment Partners Inc., Allianz Asset Management GmbH, Schroder Investment Management Group, Mitsubishi UFJ Trust & Banking Corp and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy and Rick E Winningham. View Insider Buying and Selling for Jazz Pharmaceuticals. Which institutional investors are buying Jazz Pharmaceuticals stock? JAZZ stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Bank of New York Mellon Corp, Victory Capital Management Inc., Martingale Asset Management L P, Acadian Asset Management LLC, BlackRock Inc., First Trust Advisors LP and American Century Companies Inc.. View Insider Buying and Selling for Jazz Pharmaceuticals. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $143.19. How big of a company is Jazz Pharmaceuticals? Jazz Pharmaceuticals has a market capitalization of $8.61 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe. What is Jazz Pharmaceuticals' official website? The official website for Jazz Pharmaceuticals is http://www.jazzpharma.com. How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected] MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)Community Ranking: 3.6 out of 5 ( )Outperform Votes: 831 (Vote Outperform)Underperform Votes: 313 (Vote Underperform)Total Votes: 1,144MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What is Compound Annual Growth Rate (CAGR)?